SNO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

National Cancer Institute at SNO 2026

Nov 12–15, 2026 Philadelphia, PA ~3k attendees Website

National Cancer Institute brings 12 presentations to SNO 2026 in Philadelphia. Its program covers early trials for recurrent gliomas, including IDH-mutant tumors, and metabolic vulnerabilities found in the lab. The institute also presents its funding for early-stage neuro-oncology startups.

OrganizationSNO 2026 Attendance
Government agencies
A U.S. federal institute that supports cancer research and provides information on cancer prevention, diagnosis, and treatment.
Plenary
Fri Nov 13
9:50–10am
Part of Plenary I
SYSTEMIC INFLAMMATORY PROFILES ARE ASSOCIATED WITH PHYSICAL FUNCTIONAL IMPAIRMENT IN PRIMARY BRAIN TUMORS
Exhibit Hall C, Second Floor, Convention Center · Abstract NCOG-34
Survivorship
Talk
Fri Nov 13
12:15–12:18pm
Targeting Sphingolipid–Cholesterol Crosstalk as a Metabolic Vulnerability in IDH1-Mutant Glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-04
Tumor biology
Talk
Fri Nov 13
12:27–12:30pm
SCD1 Inhibitor MF438 Drives Ferroptosis-Primed Lipidomic Reprogramming and Synergizes with Temozolomide in IDH-Mutant Glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-05
Tumor biology
Poster
Fri Nov 13
7:30–9:30pm
Correlative analysis of anti-PD-1 immunotherapy in patients with recurrent IDH-mutant gliomas
Exhibit Hall D & E, Second Floor, Convention Center · Abstract BIOM-21
Biomarkers
Poster
Fri Nov 13
7:30–9:30pm
Phase I/II Trial of PLX038 in recurrent Primary CNS Tumors with and without MYC or MYCN Amplifications: results of the phase I study
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CTNI-12
Trials
Poster
Fri Nov 13
7:30–9:30pm
Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDDR-03
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Therapeutic targeting of PIM1 disrupts mTOR signaling and mitochondrial metabolism in IDH1-mutant glioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDDR-11
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
From idea to impact: NCI funding for early-stage startups developing neuro-oncology technologies
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EXTH-64
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Longitudinal single-cell immune profiling of cerebrospinal fluid in recurrent IDH-mutant glioma receiving immune checkpoint inhibitor
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMIC-15
Tumor biology
Talk
Sat Nov 14
11:39–11:42am
Phase I/II study of zotiraciclib for recurrent malignant gliomas with IDH mutations: updated results of the phase I study
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CTNI-10
Trials
Talk
Sat Nov 14
12:15–12:18pm
PRISM: Parallel Raman Imaging with Spatial transcriptome and Multi-modal optical imaging of glioma tissue
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-06
Tumor biology
Talk
Sun Nov 15
11:14–11:21am

Explore the full SNO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Philadelphia. Leave your work email and we’ll be in touch.

Privacy

Download the full SNO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at National Cancer Institute

Tell us what you sell and we’ll find the people at National Cancer Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the Society for Neuro-Oncology. Submit a correction